Crystagen Research: Bioregulator Peptide and Eye Tissue Studies
Last updated: June 2026
Crystagen is a short peptide bioregulator derived from eye tissue. It is a dipeptide (two amino acids) linked to eye-specific proteins and studied in cell and animal models. Lab studies have examined its effects on retinal cells and visual function markers. Crystagen is not an FDA-approved drug and is available for research use only.
Next Level Pharm is a US supplier of research-grade peptides. Every vial is verified to ≥99% purity by HPLC and mass spec. A COA (certificate of analysis) ships with each order. Crystagen from Next Level Pharm is COA-verified and batch-tested. The average purity across the last 100 batches is 99.4%.
Understanding Crystagen starts with knowing what bioregulator peptides are. These are short chains derived from tissue-specific proteins. Each one is linked to the tissue of origin and studied in cell lines from that same tissue. Crystagen is the eye-tissue variant in this class.
Key Takeaways
- Crystagen Is a Short Eye-Tissue Peptide: It is a dipeptide derived from eye tissue proteins. Lab studies use it in retinal cell and animal models.
- Bioregulators Are Tissue-Linked Short Chains: Each bioregulator comes from one tissue type. They are studied in cell lines from that same tissue.
- Cell Studies Show Gene Output Effects: Cell culture models show Crystagen interacting with gene regions in retinal cells. These are in vitro findings only.
- Animal Models Record Visual Markers: Animal studies have tracked retinal thickness and VEP data. These are lab findings only.
- Research-Grade Means ≥99% Purity: Every Crystagen vial is tested by HPLC and mass spec. The COA confirms both purity and identity for each batch.
Research into Crystagen is at an early stage. Most findings come from cell culture and animal models. No human clinical trial data exists for Crystagen at this time. All findings below are at the lab stage only.
What Is Crystagen and How Is It Classified?
Crystagen is classified as a bioregulator peptide. Bioregulators are short chains derived from tissue fractions of specific organs. They are studied for their effects on gene output in the tissue of origin. Crystagen is the eye-tissue variant, derived from proteins found in retinal or ocular tissue.
The peptide is a dipeptide: two amino acids linked in sequence. Dipeptides are the shortest class of multi-amino acid chains. Their small size means they interact directly with chromatin regions. These regions sit near gene promoters in cell models. This is the proposed mechanism for gene output effects seen in cell studies.
According to a study in PubMed (2016), Khavinson lab research first identified short peptide bioregulators from tissue fractions in the 1970s. The eye-tissue variant was among the earliest studied. Cell culture findings supported the tissue-specific gene interaction hypothesis.
How Do Bioregulator Peptides Work in Cell Models?
Bioregulator peptides are thought to interact with chromatin near gene promoter regions in cell models. Chromatin is the packed form of DNA in the cell nucleus. When a peptide binds near a gene promoter, it can affect how much that gene is read into protein output. This is the proposed gene output mechanism for bioregulators.
In cell culture, researchers expose retinal cell lines to Crystagen and then measure gene output markers. If gene output changes in the expected direction, this supports the tissue-specific hypothesis. These findings are in vitro (in a dish) and do not confirm effects in living organisms.
According to a review in Molecules (2021), cell culture data for eye-tissue bioregulators showed shifts in gene output markers in retinal cell lines. The researchers noted that the findings were confined to in vitro models. Further animal and clinical study would be needed to extend these results.
What Do Animal Studies Show About Crystagen?
Animal studies on Crystagen have used rodent models with induced retinal stress or aging-related visual changes. Researchers measured retinal thickness, cell density, and VEP (visual evoked potential) signals. These are standard markers for retinal function in preclinical research.
Some animal studies reported changes in retinal thickness and photoreceptor density in Crystagen-treated groups compared to controls. Visual evoked potential data also showed signal differences in some models. These are preclinical findings and do not establish effects in humans.
Crystagen is not a treatment for any eye condition. Animal model findings have not been replicated in human trials. The research is ongoing and at an early stage.
How Does Crystagen Differ From Other Bioregulators?
Crystagen differs from other bioregulators in its tissue of origin and amino acid sequence. Each bioregulator is derived from a specific tissue. Cartalax comes from cartilage, Cardiogen from heart tissue, and Crystagen from eye tissue. They are not swappable in research models.
The amino acid sequences are distinct for each bioregulator. Cell studies use each peptide in cell lines from its own tissue of origin. Crystagen is used in retinal or ocular cell lines. This tissue focus is a core design principle of the bioregulator class.
| Peptide | Tissue of Origin | Chain Length | Primary Cell Model |
| Crystagen | Eye (retinal) | Dipeptide (2 AA) | Retinal cell lines |
| Cartalax | Cartilage | Short peptide (4 AA) | Chondrocyte cell lines |
| Cardiogen | Heart | Short peptide (4 AA) | Cardiomyocyte cell lines |
| Epithalon | Pineal gland | Short peptide (4 AA) | Fibroblast / aging models |
How Is Crystagen Tested for Research Use
Research-grade Crystagen is tested by HPLC and mass spec before it can be used in lab studies. HPLC confirms purity by showing one main peak at ≥99% of total peak area. Mass spec confirms identity by matching the found mass to the expected mass for the Crystagen dipeptide.
Both tests are needed for a research-grade batch. A batch that passes HPLC but fails mass spec would not meet the research-grade standard. A COA from a reliable supplier should show both results with the lot number for records. Shop Crystagen from Next Level Pharm with full COA data included.
What Are the Research Purity Standards for Crystagen?
Research-grade Crystagen needs ≥99% purity by HPLC and a confirmed mass spec result. These are the same standards applied to all peptides in this class. The COA should list HPLC purity as a percentage, the lot number, and the observed molecular weight from mass spec.
According to a study in Bull Exp Biol Med (2020), Khavinson lab research used HPLC-verified peptide preparations in all reported cell and animal studies. Purity above 98% was standard for all study preparations. This level of purity is considered necessary for reliable preclinical results.
Researchers should verify the COA before any lab use. A batch without a mass spec result or lot number should not be used in studies requiring full traceability.
Frequently Asked Questions
What Is Crystagen?
Crystagen is a short peptide bioregulator derived from eye tissue proteins. It is a dipeptide, meaning it has two amino acids in sequence. Lab studies have used it in retinal cell lines and rodent models with visual function markers. It is a research-grade compound and is not FDA-approved. It is available for lab research only.
What Type of Peptide Is Crystagen?
Crystagen belongs to the bioregulator peptide class. Bioregulators are short chains derived from tissue-specific protein fractions. Each is linked to one tissue of origin and studied in cell lines from that same tissue. Crystagen is the eye-tissue variant in this class. Its two-amino acid structure makes it a dipeptide, the smallest multi-amino acid chain type.
What Does Cell Research Show About Crystagen?
Cell culture studies show that Crystagen interacts with gene regions near promoters in retinal cell lines. This produces shifts in gene output markers for those cells. These are in vitro findings only. They do not confirm what happens in living organisms. Cell model results are a starting point for further study.
What Do Animal Studies Show About Crystagen?
Animal studies in rodent models have tracked retinal thickness, cell density, and VEP (visual evoked potential) signals. Some studies reported differences between Crystagen-treated groups and controls. These are lab findings only and do not establish effects in humans. Crystagen is not a treatment for any eye condition.
How Is Crystagen Different From Other Bioregulators?
Crystagen differs from other bioregulators in its tissue of origin and amino acid sequence. Cartalax comes from cartilage tissue and Cardiogen from heart tissue. Crystagen comes from eye tissue and is studied in retinal cell lines. Each bioregulator is tissue-specific and not swappable in research models.
What Purity Is Needed for Crystagen Research?
Research-grade Crystagen needs ≥99% purity by HPLC and a confirmed molecular weight by mass spec. The COA should show both results with the lot number. Batches below ≥99% purity may introduce variables that affect cell or animal study results. Always verify the COA before any lab use.
What Is the Proposed Mechanism for Crystagen?
The proposed mechanism for Crystagen in cell models is interaction with chromatin near gene promoter regions in retinal cells. This interaction is thought to affect gene output in a tissue-specific way. The mechanism is based on in vitro data from Khavinson lab research. It has not been confirmed in human studies.
Where Does Crystagen Come From?
Crystagen is a synthetic peptide produced by solid-phase peptide synthesis (SPPS). It replicates the amino acid sequence of a short chain found in eye tissue proteins. The original bioregulator class was developed by Vladimir Khavinson. Colleagues in Russia starting in the 1970s. The synthetic versions are now produced for research use worldwide.
Is Crystagen the Same as Retinalamin?
No. Retinalamin is a polypeptide complex derived from bovine retinal tissue used in some European countries. Crystagen is a short synthetic dipeptide derived from the same tissue class. They are different compounds with different structures and different research profiles. Crystagen is the synthetic two-amino acid bioregulator variant for lab research.
Summary
Crystagen is a short dipeptide bioregulator derived from eye tissue. Cell culture studies show gene output effects in retinal cell lines. Animal models have tracked retinal thickness and visual evoked potential signals as preclinical markers.
All findings are at the lab stage. Crystagen is not FDA-approved and has no human trial data. It is a research-grade compound for lab use only.
What Should You Do Next?
Researchers sourcing Crystagen should verify HPLC purity (≥99%), confirm mass spec identity, and record the lot number from the COA before any study use.
Shop research peptides. Every Crystagen batch is verified by HPLC and mass spec. Full COA data ships with each order.
People Also Read
- Epithalon Research Explained: What Current Studies Show
- What Are Longevity Peptides? A Complete Research Review
About the Author
Next Level Pharm Research Team
Alex M covers peer-reviewed findings in peptide science for Next Level Pharm, a US-based supplier of research-grade peptides verified to ≥99% purity via HPLC and mass spectrometry on every batch.
Disclaimer: The information provided on this page is for educational and research purposes only. Next Level Pharm products are intended for laboratory research use only. They are not intended for human consumption, diagnostic, therapeutic, or medicinal purposes. This content does not constitute medical advice. Always consult a licensed healthcare professional before making any health-related decisions.